Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Trial Profile

Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Cord blood stem cell therapy (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Gamida-Cell
  • Most Recent Events

    • 15 Jun 2018 Planned number of patients changed from 15 to 20.
    • 20 Feb 2018 According to a Gamida-Cell media release, data from 13 patients in this trial will be presented at the BMT Tandem Meetings (2018).
    • 20 Feb 2018 Results (n=13) published in the Gamida-Cell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top